Navigation Links
MINRAD International, Inc. Announces Change in Distribution Agreement with RxElite Holdings, Inc.

ORCHARD PARK, N.Y., Sept. 11 /PRNewswire-FirstCall/ -- MINRAD International, Inc. (Amex: BUF) today announced that it has notified RxElite Holdings, Inc., a wholly-owned subsidiary of RxElite Inc. (OTC Bulletin Board: RXEI), that it is transitioning its relationship with respect to RxElite Holdings, Inc.'s rights to be the exclusive distributor of certain Minrad International Inc.'s anesthetic products in the United States. Minrad has decided to move into a non-exclusive distributor arrangement with RxElite.

"As we discussed in our second quarter conference call on August 14, 2008, we have had ongoing dialogue with the senior management of RxElite to assess and determine how to increase our joint penetration of anesthetic products in the United States market. We believe this action will maximize the expertise of sales forces of both companies as well as the in-house support capabilities which RxElite has built to launch sevoflurane in the U.S. human anesthetic market," said David DiGiacinto, President and Chief Operating Officer.

Kirk Kamsler, Minrad's Senior Vice President, Commercial Development also commented, "We expect and will work towards ensuring that this ongoing change in selling strategy for our present and future anesthetics in the U.S. market will be transparent to both the distribution customers and end users of this product. Minrad already launched in June a direct selling effort for sevoflurane and isoflurane into the U.S. veterinary market."

Contact: David DiGiacinto, President & Chief Operating Officer

Kirk Kamsler, Senior Vice President, Commercial Development

Charles R. Trego, Jr., Executive Vice President & Chief

Financial Officer

(716) 855-1068

About the Company

MINRAD International, Inc. is an interventional pain management company with real-time image guidance, anesthesia and analgesia, conscious sedation product lines. The real-time image guidance products facilitate minimally invasive surgery especially for pain management and have broad applications in orthopedics, neurosurgery, and interventional radiology. These devices enable medical professionals to improve the accuracy of interventional procedures and reduce radiation exposure. MINRAD International also manufactures and markets generic inhalation anesthetics for use in connection with human and veterinary surgical procedures. The company is developing a drug/drug delivery system for conscious sedation, which, similar to nitrous oxide in dental surgery, provides a patient with pain relief without loss of consciousness. Additional information can be found at the company's website,

The information contained in this news release, other than historical information, consists of forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may involve risks and uncertainties that could cause actual results to differ materially from those described in such statements. Factors that may cause actual results to differ materially from those expressed or implied by its forward-looking statements include, but are not limited to, Minrad International's limited operating history and business development associated with being a growth stage company; its dependence on key personnel; its need to attract and retain technical and managerial personnel; its ability to execute its business strategy; the intense competition it faces; its ability to protect its intellectual property and proprietary technologies; its exposure to product liability claims resulting from the use of its products; general economic and capital market conditions; financial conditions of its customers and their perception of its financial condition relative to that of its competitors; as well as those risks described under the heading "Risk Factors" of Minrad International's Form 10-KSB/A, filed with the Securities and Exchange Commission on April 21, 2008. Although Minrad International, Inc. believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove to have been correct.

SOURCE MINRAD International, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. MINRAD International, Inc. Announces Appointment of Charles R. Trego, Jr. to CFO & EVP
2. MINRAD International, Inc. Announces the Start of the MINRAD International Distributor Meeting in Cape Town, South Africa
3. MINRAD International, Inc. to Discuss 2007 Fourth Quarter and Full Year Financial Results on Monday, March 31, 2008
4. MINRAD International, Inc. Announces 2007 Financial Results
5. MINRAD International, Inc. Announces FDA Approval of Petrem(TM) Sevoflurane
6. MINRAD International, Inc. to Discuss 2008 Second Quarter Financial Results on Thursday, August 14, 2008
7. Clarity Imaging International, Inc. Rolls Out Mobile DEXA Program
8. Arrow International, Inc. Invites You to Join Its 2007 Annual Meeting of Shareholders on the Web
9. Natural Alternatives International, Inc. Announces Late Filing of its Annual Report on Form 10-K, Revenue for Fiscal 2007 and Guidance on First Quarter of Fiscal 2008
10. Cryo-Cell International, Inc. Reports Third Quarter 2007 Results
11. TenderCare International, Inc. Announces Signing of Merger Agreement with the Hain Celestial Group for All Outstanding Shares of TenderCare Stock
Post Your Comments:
(Date:11/27/2015)... CA (PRWEB) , ... November 27, 2015 , ... According ... at the recent 2015 American Dental Association meeting in Washington D.C. revolved around the ... protect a patient’s overall health. The talk stressed the link between periodontal disease (more ...
(Date:11/27/2015)... ... November 27, 2015 , ... The ... in America. As people age, more care is needed, especially with Alzheimer’s, dementia ... medical professionals are being overworked. The forgotten part of this equation: 80 percent ...
(Date:11/27/2015)... ... November 27, 2015 , ... "When I was traveling, ... from Hillside, N.J. "Many people catch diseases simply from sitting on such dirty ... be protected from germs." , He developed the patent-pending QUDRATECS to eliminate the ...
(Date:11/27/2015)... ... 27, 2015 , ... ProSidebar: Fashion is a set of 30 ... ProSidebar: Fasion, video editors can easily add an informative sidebar to any FCPX production. ... Utilize presets featuring self-animating drop zones, lines, bars, and text with the ease of ...
(Date:11/27/2015)... ... November 27, 2015 , ... Intellitec ... Dynamics SL User Group (MSDSLUG). Recognized as Microsoft’s official group for end users ... Dynamics SL software users, partners, industry experts and representatives. Intellitec Solutions’ membership status ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... , Nov. 26, 2015 Research ... addition of the "2016 Future Horizons and ... (TDM) Market: Supplier Shares, Country Segment Forecasts, Competitive ... --> --> ... analysis of the Italian therapeutic drug monitoring market, ...
(Date:11/25/2015)... 25, 2015 ... the "Global Brain Monitoring Devices Market ... --> ) has announced the ... Devices Market 2015-2019" report to their ... ( ) has announced the addition ...
(Date:11/25/2015)... 25, 2015  The American Academy of Pediatrics ... and the March of Dimes cheered today,s signature ... Infants Act of 2015 (S.799), which takes ... born exposed to drugs, such as opioids, and ... all three organizations have worked together leading advocacy ...
Breaking Medicine Technology: